GEODE CAPITAL MANAGEMENT, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 18 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$127,000
-54.2%
385,6450.0%0.00%
Q2 2020$277,000
+121.6%
385,6450.0%0.00%
Q1 2020$125,000
-76.9%
385,645
-50.0%
0.00%
Q4 2019$540,000
+227.3%
771,290
+216.6%
0.00%
Q3 2019$165,000
-59.2%
243,6330.0%0.00%
Q2 2019$404,000
-32.2%
243,633
+2.2%
0.00%
Q1 2019$596,000
-46.1%
238,453
-45.3%
0.00%
Q4 2018$1,106,000
+15.7%
435,930
+130.1%
0.00%
Q3 2018$956,000
+54.9%
189,4930.0%0.00%
Q2 2018$617,000
-6.5%
189,493
+3.9%
0.00%
Q1 2018$660,000
+1550.0%
182,401
+818.5%
0.00%
Q4 2017$40,000
+21.2%
19,8590.0%0.00%
Q3 2017$33,000
-36.5%
19,8590.0%0.00%
Q2 2017$52,000
-62.0%
19,8590.0%0.00%
Q1 2017$137,000
+211.4%
19,8590.0%0.00%
Q4 2016$44,000
-4.3%
19,8590.0%0.00%
Q3 2016$46,000
-9.8%
19,8590.0%0.00%
Q2 2016$51,000
-8.9%
19,8590.0%0.00%
Q1 2016$56,000
-34.9%
19,8590.0%0.00%
Q4 2015$86,000
-43.0%
19,8590.0%0.00%
Q3 2015$151,00019,8590.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2017
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,675,889$6,797,0005.97%
PERKINS CAPITAL MANAGEMENT INC 449,950$1,143,0000.89%
Diametric Capital, LP 116,754$297,0000.23%
Granahan Investment Management 924,300$2,348,0000.17%
Requisite Energy Fund I LP 100,000$254,0000.10%
Requisite Capital Management, LLC 100,000$254,0000.10%
B. Riley Wealth Advisors, Inc. 250,000$635,0000.09%
Kalos Management, Inc. 74,420$179,0000.09%
Crow Point Partners, LLC 65,475$164,0000.03%
ARDSLEY ADVISORY PARTNERS LP 35,000$89,0000.02%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders